SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nakano KK. Anencephaly: a review. Dev Med Child Neurol 1973;15: 383400.
  • 2
    Thomas JA, Markovac J, Ganong WF. Anencephaly and other neural tube defects. Front Neuroendocrinol 1994;15: 197201.
  • 3
    Hunter AG. Brain and spinal cord. In: StevensonRE, HallJG, GoodmanRM, eds. Human malformations and related anomalies. New York : Oxford University Press, 1993: 10937.
  • 4
    Golden JA, Chernoff GF. Intermittent pattern of neural tube closure in two strains of mice. Teratology 1993;47: 7380.
  • 5
    Van Allen MI, Kalousek DK, Chernoff GF, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993;47: 72343.
  • 6
    Echelard Y, Epstein DJ, St-Jacques B, et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 1993;75: 141730.
  • 7
    Ewart JL, Cohen MF, Meyer RA, et al. Heart and neural tube defects in transgenic mice overexpressing the Cx43 gap junction gene. Development 1997;124: 128192.
  • 8
    Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995;10: 17580.
  • 9
    Zhang J, Hagopian-Donaldson S, Serbedzija G, et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996;381: 23841.
  • 10
    Shum AS, Copp AJ. Regional differences in morphogenesis of the neuroepithelium suggest multiple mechanisms of spinal neurulation in the mouse. Anat Embryol (Berl) 1996;194: 6573.
  • 11
    Macdonald KB, Juriloff DM, Marris MJ. Developmental study of neural tube closure in a mouse stock with a high incidence of exencephaly. Teratology 1989;39: 195213.
  • 12
    Lemire RJ. Neural tube defects. JAMA 1988;259: 58862.
  • 13
    Haque M, Takami T, Soures SB Jr, Aree SN, Hakuba A, Hara M. Development of lumbosacral spina bifida: three-dimensional computer graphic study of human embryos at Carnegie stage twelve. Pediatr Neurosurg 2001;35: 24752.
  • 14
    O'Rahilly R, Müller F. The two sites of fusion of the neural tube and the two neuropores in the human embryo. Teratology 2002;65: 16270.
  • 15
    Van Straaten HW, Copp AJ. Curly tail: a 50-year history of the mouse spina bifida model. Anat Embryol (Berl) 2001;203: 22537.
  • 16
    Copp AJ, Seller MJ, Polani PE. Neural tube development in mutant (curly tail) and normal mouse embryos: the timing of posterior neuropore closure in vivo and in vitro. J Embryol Exp Morphol 1982;69: 1516.
  • 17
    Copp AJ. Relationship between timing of posterior neuropore closure and development of spinal neural tube defects in mutant (curly tail) and normal mouse embryos in culture. J Embryol Exp Morphol 1985;88: 3954.
  • 18
    Van Straaten HW, Hekking JW, Copp AJ, Bernfield M. Deceleration and acceleration in the rate of posterior neuropore closure during neurulation in the curly tail (ct) mouse embryo. Anat Embryol (Berl) 1992;185: 16974.
  • 19
    Harris MJ. Why are the genes that cause risk of human neural tube defects so hard to find? Teratology 2001;63: 1656.
  • 20
    Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327: 18325.
  • 21
    Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995;6: 21926.
  • 22
    Finnell RH, Greer KA, Barber RC, Piedrahita JA, Shaw GM, Lammer EJ. Neural tube and craniofacial defects with special emphasis on folate pathway genes. Crit Rev Oral Biol Med 1998;9: 3853.
  • 23
    Ramsbottom D, Scott JM, Molloy A, et al. Are common mutations of cystathionine beta-synthase involved in the aetiology of neural tube defects? Clin Genet 1997;51: 3942.
  • 24
    Morrison K, Papapetrou C, Hol FA, et al. Susceptibility to spina bifida: an association study of five candidate genes. Ann Hum Genet 1998;62(pt 5):37996.
  • 25
    Hol FA, Van Der Put NM, Geurds MP, et al. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydro folate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet 1998;53: 11925.
  • 26
    Heil SG, Van der Put NM, Waas ET, Den Heijer M, Trijbels FJ, Blom HJ. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001;73: 16472.
  • 27
    Shaw GM, Lammer EJ, Zhu H, Baker MW, Neri E, Finnell RH. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002;108: 16.
  • 28
    Barber RC, Shaw GM, Lammer EJ, et al. Lack of association between mutations in the folate receptor-alpha gene and spina bifida. Am J Med Genet 1998;76: 3107.
  • 29
    De Marco P, Moroni A, Merello E, et al. Folate pathway gene alterations in patients with neural tube defects. Am J Med Genet 2000;95: 21623.
  • 30
    Trembath D, Sherbondy AL, Vandyke DC. Analysis of selected folate pathway genes, PAX3, and human T in a Midwestern neural tube defect population. Teratology 1999;59: 33141.
  • 31
    Saikawa Y, Price K, Hance KW, Chen TY, Elwood PC. Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. Biochemistry 1995;34: 995161.
  • 32
    Barber R, Shalat S, Hendricks K, et al. Investigation of folate pathway gene polymorphisms and the incidence of neural tube defects in a Texas hispanic population. Mol Genet Metab 2000;70: 4552.
  • 33
    Frosst P, Blom HJ, Milos R, et al. A candidate risk factor for cardiovascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10: 1113.
  • 34
    Van Der Put NMJ, Van Den Heuvel LP, Steegers-Theunissen RPM0, et al. Decreased methylenetetrahydrofolate reductase activity due to the 677 C-T mutation in families with spina bifida offspring. J Mol Med 1996;74: 6914.
  • 35
    Botto LD, Yang Q. 5-10 Methylenetetrahydrofolate reductase variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151: 86277.
  • 36
    Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 1998;148: 307.
  • 37
    Martinez de Villarreal LE, Delgado-Eneiso I, Valdez-Leal R, et al. Folate levels and N(5),N(10) methylenetetrahydrofolate reductase genotype (MTHFR) in mothers of offspring with neural tube defects: a case-control study. Arch Med Res 2001;32: 27782.
  • 38
    Volcik KA, Blanton SH, Tyerman GH, et al. Methylenetetrahydrofolate reductase and spina bifida: evaluation of level of defect and maternal genotype risk in Hispanics. Am J Med Genet 2000;95: 217.
  • 39
    Juriloff DM, Harris MJ. Mouse models for neural tube closure defects. Hum Mol Genet 2000;9: 9931000.
  • 40
    Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RG. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988;263: 136029.
  • 41
    Weitman SD, Lark RH, Coney LR, et al. Distribution of folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52: 3396401.
  • 42
    Piedrahita JA, Oetama B, Bennett GD, et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet 1999;23: 22832.
  • 43
    Finnell RH, Spiegelstein O, Wlodarczyk B, et al. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J Nutr 2002;132(suppl 8):2457S61S.
  • 44
    Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci USA 1996;93: 1522732.
  • 45
    Steegers-Theunissen R, Boers G, Tribels FJ, Eskes TK. Neural-tube defects and derangement of homocysteine metabolism. N Engl J Med 1991;324: 199200.
  • 46
    Langman LJ, Cole DE. Homocysteine. Crit Rev Clin Lab Sci 1999;36: 365406.
  • 47
    Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19: 21746.
  • 48
    Gelineau-van Waes J, Finnell RH. Genetics of neural tube defects. Semin Pediatr Neurol 2001;8: 1604.
  • 49
    Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 1999;56: 21620.
  • 50
    Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5: 186774.
  • 51
    Ma J, Stampfer MJ, Christiansen B, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocysteine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8: 8259.
  • 52
    Christiansen B, Arbour L, Tran P, et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 1999: 84: 1517.
  • 53
    Van Der Put NMJ, Eskes TKAB, Blom HJ. Is the common C677C [RIGHTWARDS ARROW] T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Q J Med 1997;90: 1115.
  • 54
    Brody LC, Baker PJ, Chines PS, et al. Methionine synthase: resolution mapping of the human gene and evaluation as a candidate locus for neural tube defects. Mol Genet Metab 1999;67: 32433.
  • 55
    Morrison K, Edwards YH, Lynch SA, Burn J, Hol F, Mariman E. Methionine synthase and neural tube defects. J Med Genet 1997;34: 958.
  • 56
    Shaw GM, Todoroff K, Finnell RH, et al. Infant methionine synthase variants and risk for spina bifida. J Med Genet 1999;36: 867.
  • 57
    Chen J, Zhang I, Cheng L, Li Y. The effect of polymorphisms of MTHER gene and vitamin B on hyperhomocysteinemia. J Tongji Med Univ 2001;21: 1720.
  • 58
    Rosenblatt DS, Cooper BA, Pottier A, Lue-Shing H, Matiaszuk N, Grauer K. Altered vitamin B12 metabolism in fibroblasts from a patient with megaloblastic anemia and homocystinuria due to a new defect in methionine biosynthesis. J Clin Invest 1984;74: 214956.
  • 59
    Leclerc D, Wilson A, Dumas R, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocysteinuria. Proc Natl Acad Sci USA 1998;95: 305964.
  • 60
    Wilson A, Leclerc D, Rosenblatt DS, Gravel RA. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum Mol Genet 1999;8: 200916.
  • 61
    Hobbs CA, Sherman SL, Yi P, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 2000;67: 62330.
  • 62
    O'Leary VB, Parle-McDermott A, Molloy AM, et al. MTRR and MTHFR polymorphism: link to Down syndrome? Am J Med Genet 2002;107: 1515.
  • 63
    Gaughan DJ, Kluijtmans LA, Barbaux S, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001;157: 4516.
  • 64
    Zhu H, Wicker NJ, Shaw GM, et al. Double mutants of MTR A2756G and MTRR A66G with increased risk of neural tube defects (NTDs). Mol Genet Metab 2003;78: 21621.
  • 65
    Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology 1987;35: 46573.
  • 66
    Bjerkendal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida. Lancet 1982;2: 1096.
  • 67
    Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108: 9971004.
  • 68
    Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1986;1: 13923.
  • 69
    Nau H, Hendrickx AG. Valproic acid teratogenesis. ISI Atlas of Science: Pharmacology 1987;1: 526.
  • 70
    Finnell RH, Bennett GD, Karras SB, Mohl VK. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988;38: 31320.
  • 71
    Nau H. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 1985;80: 24350.
  • 72
    Niedermeyer E. Epilepsy guide: diagnosis and treatment of epileptic seizure disorders. Baltimore-Munich : Urban & Schwarzenberg , 1983.
  • 73
    Ehlers K, Sturje H, Merker H, Nau H. Valproic acid-induced spina bifida: a mouse model. Teratology 1992;45: 14554.
  • 74
    Ehlers K, Sturje H, Merker H, Nau H. Spina bifida aperta induced by valproic acid and by all-trans-retinoic acid in the mouse: distinct differences in morphology and periods of sensitivity. Teratology 1992;46: 11730.
  • 75
    Wegner C, Nau H. Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic-acid-induced teratogenicity is time dependent. Reprod Toxicol 1991;5: 46571.
  • 76
    Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. Neurology 1992;42(4 suppl 5):1724.
  • 77
    Martin ML, Regan CM. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res 1991;554: 2238.
  • 78
    Regan CM, Gorman AM, Larsson OM, et al. In vitro screening for anticonvulsant-induced teratogenesis in neural primary cultures and cell lines. Int J Dev Neurosci 1990;8: 14350.
  • 79
    Finnell RH, Wlodarczyk BC, Craig JC, Piedrahita JA, Bennett GD. Strain dependent alterations in the expression of folate pathway genes following teratogenic exposure to valproic acid in a mouse model. Am J Med Genet 1997;70: 30311.
  • 80
    Finnell RH, Vacha SJ, Mackler SA. Nucleic acid amplification technologies. In: DastonG, ed. Molecular and cellular methods in developmental toxicology. Boca Raton , FL : CRC Press, 1997: 93125.
  • 81
    Finnell RH, Junker WM, Wadman LK, Cabrera RM. Gene expression profiling within the developing neural tube. Neurochem Res 2002;27: 116580.
  • 82
    Finnell RH, Dansky LV. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 1: Animal studies. Reprod Toxicol 1991;5: 28199.
  • 83
    Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153: 9618.
  • 84
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324: 6747.
  • 85
    Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16: 917.